BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, potentially reversible side effect of some chemotherapeutic agents. CIPN is associated with decreased balance, function and quality of life (QoL). This association has to date been under-investigated. AIMS: To profile patients presenting with CIPN using the modified Total Neuropathy Score (mTNS) in this cross-sectional study and to examine the relationship between CIPN (measured by mTNS) and indices of balance, quality of life (QoL) and function. METHODS: Patients receiving neurotoxic chemotherapy regimens were identified using hospital databases. Those who did not have a pre-existing neuropathy were invited to complete mTNS, Berg Balance Scale (BBS), timed up and go (TUG), and FACT-G QoL questionnaire. mTNS scores were profiled and also correlated with BBS, TUG and FACT-G using Spearmans correlation coefficient. RESULTS: A total of 29 patients undergoing neurotoxic chemotherapy regimens were tested. The patients mTNS scores ranged between 1 and 12 (median = 5), indicating that all patients had clinical evidence of neuropathy on mTNS. No significant correlations were found between mTNS and BERG (r = -0.29), TUG (r = 0.14), or FACT-G (r = 0.05). CONCLUSIONS: This study found a high prevalence of CIPN in patients treated with neurotoxic chemotherapy regimens. The mTNS provided a clinically applicable, sensitive screening tool for CIPN which could prove useful in clinical practice. mTNS did not correlate with BBS, TUG or FACT-G in this sample, possibly due to relatively mild levels of CIPN and consequent subtle impairments which were not adequately captured by gross functional assessments.
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, potentially reversible side effect of some chemotherapeutic agents. CIPN is associated with decreased balance, function and quality of life (QoL). This association has to date been under-investigated. AIMS: To profile patients presenting with CIPN using the modified Total Neuropathy Score (mTNS) in this cross-sectional study and to examine the relationship between CIPN (measured by mTNS) and indices of balance, quality of life (QoL) and function. METHODS:Patients receiving neurotoxic chemotherapy regimens were identified using hospital databases. Those who did not have a pre-existing neuropathy were invited to complete mTNS, Berg Balance Scale (BBS), timed up and go (TUG), and FACT-G QoL questionnaire. mTNS scores were profiled and also correlated with BBS, TUG and FACT-G using Spearmans correlation coefficient. RESULTS: A total of 29 patients undergoing neurotoxic chemotherapy regimens were tested. The patients mTNS scores ranged between 1 and 12 (median = 5), indicating that all patients had clinical evidence of neuropathy on mTNS. No significant correlations were found between mTNS and BERG (r = -0.29), TUG (r = 0.14), or FACT-G (r = 0.05). CONCLUSIONS: This study found a high prevalence of CIPN in patients treated with neurotoxic chemotherapy regimens. The mTNS provided a clinically applicable, sensitive screening tool for CIPN which could prove useful in clinical practice. mTNS did not correlate with BBS, TUG or FACT-G in this sample, possibly due to relatively mild levels of CIPN and consequent subtle impairments which were not adequately captured by gross functional assessments.
Authors: Andreas A Argyriou; Panagiotis Polychronopoulos; Angelos Koutras; Gregoris Iconomou; Philippos Gourzis; Konstantinos Assimakopoulos; Haralabos P Kalofonos; Elisabeth Chroni Journal: Support Care Cancer Date: 2005-07-15 Impact factor: 3.603
Authors: Madeleine T King; Martin R Stockler; David F Cella; David Osoba; David T Eton; Joanna Thompson; Amy R Eisenstein Journal: J Clin Epidemiol Date: 2009-08-27 Impact factor: 6.437
Authors: Mitra Varedi; Lu Lu; Carrie R Howell; Robyn E Partin; Melissa M Hudson; Ching-Hon Pui; Kevin R Krull; Leslie L Robison; Kirsten K Ness; Raymond F McKenna Journal: J Clin Oncol Date: 2018-05-29 Impact factor: 44.544
Authors: Stephen Sands; Elena J Ladas; Kara M Kelly; Michael Weiner; Meiko Lin; Deborah Hughes Ndao; Amie Dave; Linda T Vahdat; Julia Glade Bender Journal: Support Care Cancer Date: 2016-11-09 Impact factor: 3.603
Authors: Tito R Mendoza; Xin Shelley Wang; Loretta A Williams; Qiuling Shi; Elisabeth G Vichaya; Patrick M Dougherty; Sheeba K Thomas; Emre Yucel; Christel C Bastida; Jeanie F Woodruff; Charles S Cleeland Journal: J Pain Date: 2015-07-22 Impact factor: 5.820
Authors: Xin Shelley Wang; Qiuling Shi; Patrick M Dougherty; Cathy Eng; Tito R Mendoza; Loretta A Williams; David R Fogelman; Charles S Cleeland Journal: Oncology Date: 2016-02-17 Impact factor: 2.935
Authors: Ian R Kleckner; Richard F Dunne; Matthew Asare; Calvin Cole; Fergal Fleming; Chunkit Fung; Po-Ju Lin; Karen M Mustian Journal: Oncol Hematol Rev Date: 2018-02-15
Authors: Mohammed S Ezzi; Nicholas A Othieno-Abinya; Erastus Amayo; Peter Oyiro; Angela McLigeyo; Robert Bett Yatich; Bonginkosi Shoba Journal: J Glob Oncol Date: 2019-09
Authors: Deanna Saylor; Gertrude Nakigozi; Noeline Nakasujja; Kevin Robertson; Ronald H Gray; Maria J Wawer; Ned Sacktor Journal: Neurology Date: 2017-07-05 Impact factor: 9.910